People · Operator
Named in public records as an officer, director or promoter · active 2017–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OncoC4, Inc. | — | Biotechnology | Series C | $50.0M | $1.7B | 2020 |
| OncoImmune, Inc. | — | Biotechnology | Series A | $8.5M | $108.5M | 2017 |
Martin Devenport at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Martin Devenport on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Yang Liu | 2 | 3 |
| KAREN LIU | 1 | 4 |
| Miao Hong | 1 | 2 |
| Michael Flaschen | 1 | 1 |
| Gary Fanger | 1 | 1 |
| Pan Zheng | 1 | 1 |
| Kun-Liang Guan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.